These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 33507482)
1. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series. Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482 [TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
4. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
5. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related]
6. Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer. Mampel A; Sottile ML; Denita-Juárez SP; Vargas AL; Vargas-Roig LM Cancer Genet; 2022 Jan; 260-261():14-17. PubMed ID: 34801929 [TBL] [Abstract][Full Text] [Related]
7. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243 [TBL] [Abstract][Full Text] [Related]
8. Double Heterozygosity for Rare Deleterious Variants in the Madar L; Majoros V; Szűcs Z; Nagy O; Babicz T; Butz H; Patócs A; Balogh I; Koczok K Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895014 [TBL] [Abstract][Full Text] [Related]
9. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond Evans DG; Burghel GJ; Howell SJ; Pugh S; Forde C; Howell A; Lalloo F; Woodward ER J Med Genet; 2024 Aug; 61(9):853-855. PubMed ID: 38609177 [TBL] [Abstract][Full Text] [Related]
10. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081 [TBL] [Abstract][Full Text] [Related]
11. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips]. Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related]
13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152 [TBL] [Abstract][Full Text] [Related]
15. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas. Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants. Wen S; Zhang M; Chen J; Hu L; Sun J; Yao L; Xu Y; Zhang J; Xie Y Breast Cancer Res Treat; 2024 Nov; 208(1):155-164. PubMed ID: 38900213 [TBL] [Abstract][Full Text] [Related]
19. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients. Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917 [TBL] [Abstract][Full Text] [Related]
20. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]